Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 7/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13013499 | 0.96 | PIM1 (0.38) | PIM1TGFBR1PIM2PIM3OPRM1 | |
| SCHEMBL3721474 | 0.88 | TYK2 (0.43) | PIM1NTRK1 | |
| SCHEMBL3721470 | 0.88 | TYK2 (0.43) | PIM1NTRK1 | |
| SCHEMBL13013500 | 0.87 | TGFBR1 (0.36) | PIM1TGFBR1PIM2PIM3TGFBR2 | |
| SCHEMBL13013501 | 0.86 | PIM1 (0.34) | PIM1TGFBR1PIM2PIM3TGFBR2 | |
| SCHEMBL13013508 | 0.85 | IRAK4 (0.34) | PIM1TGFBR1TGFBR2 | |
| SCHEMBL3722482 | 0.85 | TYK2 (0.42) | CDK2 | |
| SCHEMBL3722474 | 0.85 | TYK2 (0.42) | CDK2 | |
| SCHEMBL3780555 | 0.81 | TYK2 (0.45) | CDK2 | |
| SCHEMBL3780569 | 0.81 | TYK2 (0.45) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2009100375-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP4K2, MAP3K15 | PIM1 42/4885TGFBR1 2134/4885PIM2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.